EGFR and non-small cell lung carcinoma: In addition, Sakata et al. reported that when severe AEs occur, especially hepatotoxicity, switching EGFR-TKIs or temporary drug withdrawal may improve the prognosis of patients with EGFR mutation-positive NSCLC [16].﻿ In a pooled analysis of 21 prospective clinical trials conducted between 2004 and 2014, the incidence of severe hepatotoxicity with elevated AS﻿T﻿ or alanine aminotransferase (ALT) of Grade ≥ 3 on the Common Terminology Criteria for Advanced Events (CTCAE) was 18.0% for gefitinib and 5.4% for erlotinib.